Oruka's ORKA-001: Owning the Ultra-Long-Dose End of Psoriasis

Hook & Thesis

Oruka Therapeutics has quietly moved from curiosity to credible threat in psoriasis. Recent Week 28 data from the EVERLAST-A Phase 2a cohort showed deepening responses without redosing - 71.4% PASI 100 and 87.3% PASI 90 at six months after a dosing series that ended at Week 4 (reported 09/23/2026). That durability - combined with a once-yearly dosing profile - creates a commercial proposition that is simple to explain to payers and attractive to patients: fewer visits, fewer shots, and higher complete-clearance rates.

My trade thesis is straightforward: the psoriasis market is becoming a barbell - frequent-dosing incumbents on one end and a handful of ultra-long-acting biologics on the other - and ORKA-001 owns the far end. If ORKA-001 translates its Phase 2 durability into pivotal success and secures pricing that reflects both clinical superiority and convenience, Oruka's current valuation (market cap roughly $4.76B) understates potential upside. This is an event-driven, clinical-risk-heavy, but data-backed long idea with tight risk management.

Company overview - What Oruka does and why the market should care

Oruka Therapeutics is a clinical-stage biotech focused on monoclonal antibodies for psoriasis and other inflammatory and immune-mediated diseases. Its lead program, ORKA-001, targets IL-23p19 and is designed for extended durability. The company also has ORKA-002 in earlier stages and has been building out a commercial organization - hiring Todd Edwards as Chief Commercial Officer (effective 08/24/2026) to prepare for potential launch.

Why the market should care: psoriasis is a large, well-funded specialty market where incremental improvements in efficacy and dosing convenience translate directly into price and volume. AbbVie’s market-leading drugs demonstrate the category’s willingness to pay for sustained skin clearance. A product that can deliver PASI 100 rates north of incumbent benchmarks while requiring annual administration is strategically valuable - it disrupts prescribing patterns and creates a premium pricing leverage point with payers.

Support from the data

• Clinical: EVERLAST-A Week 28 interim results (reported 09/23/2026) show 71.4% PASI 100 and 87.3% PASI 90 at six months post-last dose with no additional dosing after Week 4.
• Market and liquidity: shares trade around $72.01 (current price) with a market cap near $4.76B and enterprise value roughly $4.49B. The 52-week range is $25.11 to $115.52 (high on 08/19/2026), giving a sense of how sentiment has swung over the past year.
• Financial posture: EPS currently negative (-$1.74) and free cash flow negative (-$101.154M per the latest reporting), but the company completed an upsized public offering that generated approximately $700.4M in gross proceeds (priced 04/28/2026), indicating an intent to fund development and launch activities.
• Commercial preparedness: hiring of a seasoned CCO on 08/24/2026 signals management believes the asset can enter late-stage development and ultimately the market; that’s a concrete operational read.
• Technical setup: the stock sits below short-term moving averages (10-, 20-, 50-day SMAs are $78.45, $82.49, $92.57 respectively), RSI around 28 indicates oversold territory, and there is meaningful short interest (~7.7M shares as of 09/30/2026), so momentum can flip quickly on fresh news.

Valuation framing

At a market cap near $4.76B and an enterprise value near $4.49B, the market is pricing Oruka as a high-growth clinical-stage company with significant commercial potential priced for perfection in ORKA-001’s outcomes. There is no listed revenue for the lead program and the company is operating at a loss, so conventional multiple comparisons are not directly applicable. Instead, valuation should be thought of as a function of: (1) probability-weighted commercialization of ORKA-001; (2) launch pricing and market share vs incumbents; (3) success of ongoing and future pivotal trials.

Qualitatively, if ORKA-001 can command premium pricing versus current IL-23 agents because it combines higher PASI 100 rates with once-yearly dosing, a modest share of the multi-billion-dollar psoriasis market justifies a multi-billion dollar valuation. Conversely, if the drug fails to demonstrate durable superiority in pivotal testing or faces payers resistant to premium pricing, the valuation resets much lower. That binary is why the trade has asymmetric upside but carries real downside clinical risk.

Catalysts

• Full 52-week EVERLAST-A data expected in December 2026 - this is the next major clinical read that could materially re-rate the stock (positive) or compress upside (if durability or safety questions emerge).
• Initiation of pivotal trials or regulatory guidance that clarifies the path to approval - will determine the timing and likelihood of commercialization.
• Commercial hires and payer engagement progress following the CCO appointment (08/24/2026) - concrete commercialization planning reduces execution risk.
• Partnership talks or licensing deals - a strategic partner could accelerate rollout and de-risk commercialization, materially impacting valuation.

Trade plan - actionable and time-boxed

Trade idea: Long Oruka Therapeutics (ORKA) at an entry price of $72.01. This is a long-term trade meant to capture re-rating around late-stage clinical readouts and commercial progress.

Parameters:

• Entry: $72.01 (current price)
• Stop loss: $58.00 - a decisive technical break below this level would indicate weakening conviction and would protect downside capital.
• Target: $130.00 over the long term (180 trading days) - the target captures potential re-rating if Phase 2 durability is confirmed at 52 weeks and pivotal progress/launch messaging accelerates.
• Horizon: long term (180 trading days) - allow time for the 12-month durability data to flow, for potential pivotal trial starts, and for the market to digest commercial staffing and payer positioning.

Why this timeframe: clinical and commercial catalysts rarely resolve within a few weeks. The next meaningful data point is 52-week results due in December 2026; the 180 trading day horizon gives the trade room to capture post-data rerating and subsequent program-enabling announcements. If you prefer a faster approach, consider trimming position into quick positive headlines and re-enter on pullbacks; but the core conviction is driven by durable clinical outcomes and commercial optionality, which take months to crystalize.

Risks and counterarguments

Below are the major risks that could invalidate this trade, and a counterargument to the bullish thesis.

• Clinical risk: Phase 2 durability is promising but not definitive. Pivotal trials can fail to replicate Phase 2 magnitude or durability, which would materially damage the upside case.
• Safety surprises: While the Phase 2 safety profile was consistent with the IL-23 class, delayed or rare adverse events can appear in larger populations and derail regulatory timelines or price.
• Payer resistance and pricing pressure: Even with better PASI 100, payers could resist premium pricing for once-yearly dosing if cost-effectiveness models do not support the price premium, especially if biosimilars or next-gen incumbents compress pricing.
• Execution risk: Oruka is still small (about 68 employees) and will need to scale commercial and manufacturing operations. Execution missteps in supply chain, partner selection, or go-to-market strategy could blunt launch potential.
• Counterargument - incumbents and payer inertia could blunt ORKA-001’s pricing power: AbbVie and other large players have entrenched relationships with dermatologists and payers. Even superior efficacy may face formulary hurdles and step therapy requirements that slow adoption, keeping revenue growth muted despite a high clinical bar.
• Share volatility and insider sales: The company has seen insider sales and large personnel option exercises in 2026. While some sales were pre-planned, investor perception around insider activity can increase volatility and reduce near-term upside.

What would change my mind

I would reduce or flip the position if any of the following occur: (1) 52-week EVERLAST-A data (expected 12/2026) shows materially lower PASI 100 durability or safety signals; (2) the company provides guidance that materially delays pivotal starts or reduces likelihood of filing; (3) commercial feedback indicates payers are unlikely to support premium pricing or annual administration; or (4) share price breaks and holds below $58 on accelerating volume, confirming technical breakdown.

Conclusion

Oruka sits at a high-upside intersection: superior complete clearance rates combined with once-yearly dosing present a rare commercial proposition in psoriasis. The company is capitalized to run pivotal programs and has signaled commercial intent with experienced hires. That combination makes ORKA-001 a candidate to own for event-driven, high-risk-tolerant investors who want exposure to a potential category-defining therapy.

This trade is not for the risk-averse: negative trial updates, payer pushback, or execution issues can quickly compress the stock. For investors who accept that clinical risk, a long position entered at $72.01 with a stop at $58.00 and a long-term target of $130.00 balances upside potential against disciplined downside protection.

Quick reference table

Bottom line: ORKA-001 is a high-conviction, high-volatility long tied to durability and commercialization execution. If you believe once-yearly dosing plus superior PASI 100 will win share in psoriasis, this is a trade to size and manage actively.